Comparative Pharmacology
Head-to-head clinical analysis: TESTOPEL versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
Head-to-head clinical analysis: TESTOPEL versus TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE.
TESTOPEL vs TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to and activates androgen receptors, leading to changes in gene expression that promote male sexual development, maintenance of secondary sexual characteristics, and anabolic effects.
Testosterone enanthate is a prodrug of testosterone, which binds to androgen receptors, activating gene transcription that leads to development of male secondary sex characteristics and anabolic effects. Estradiol valerate is a prodrug of estradiol, which binds to estrogen receptors, promoting growth and development of female reproductive tissues and secondary sex characteristics.
Subcutaneous implantation: 150-450 mg every 3-6 months. Individualize based on serum testosterone levels and clinical response.
1 to 2 mL of a combination product containing 90 mg testosterone enanthate and 4 mg estradiol valerate per mL intramuscularly every 4 weeks.
None Documented
None Documented
Terminal half-life: 8-10 days; due to prolonged release from subcutaneous depot, effective half-life extends to 2-3 weeks.
Testosterone enanthate: 4-5 days (IM). Estradiol valerate: 2-3 days (IM). Steady-state reached in ~2-3 weeks.
Renal: ~90% as glucuronide and sulfate conjugates, ~10% unchanged; fecal: ~6% via biliary elimination.
Testosterone enanthate and estradiol valerate are metabolized in the liver. Testosterone metabolites (e.g., androsterone, etiocholanolone) are conjugated and excreted renally (90%) and fecally (~10%). Estradiol valerate is hydrolyzed to estradiol, metabolized to estrone and estriol, conjugated, and excreted primarily renally (70-80%) with ~20% biliary/fecal.
Category C
Category D/X
Androgen
Androgen